Assessment of plasma GM-CSF may be sufficient to identify patients receiving anti-GM-CSF antibodies who are at increased risk of developing aPAP and require further medical evaluation. The gene discussed is CSF2; the disease is autoimmune pulmonary alveolar proteinosis.